<SEC-DOCUMENT>0001193125-15-171831.txt : 20150505
<SEC-HEADER>0001193125-15-171831.hdr.sgml : 20150505
<ACCEPTANCE-DATETIME>20150505151333
ACCESSION NUMBER:		0001193125-15-171831
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150505
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150505
DATE AS OF CHANGE:		20150505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		15832324

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d921398d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;5, 2015 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO
PHARMACEUTICALS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 100</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting,&nbsp;Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19422</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: <U>(267)&nbsp;440-4200</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><U></U></B><U>Item&nbsp;8.01<B></B></U><B></B>.<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><U></U></B><U>Other Events<B></B></U><B></B>.<B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2015, Inovio
Pharmaceuticals, Inc. (the &#147;Company&#148;) announced that it closed its underwritten public offering with respect to 10,925,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;Common Stock&#148;), including
1,425,000 shares of common stock issued pursuant to the underwriter&#146;s exercise of its option, at the public offering price of $8.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gross proceeds of the offering were $87.4 million. Net proceeds to the Company, after deducting the underwriter&#146;s discounts and
commission and other estimated offering expenses payable by the company, were approximately $82.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Piper Jaffray&nbsp;&amp; Co.
and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated acted as joint bookrunning managers for the offering. H.C. Wainwright&nbsp;&amp; Co., LLC, Brean Capital, LLC and Maxim Group LLC acted as co-managers of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds received from the sale of the Common Stock for general corporate purposes, including clinical
trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies and technologies that complement its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock was issued pursuant to a registration statement on Form S-3 that the Company filed with the Securities and Exchange
Commission, which became effective on August&nbsp;8, 2014 (File No.&nbsp;333-197584). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2015, the Company issued a press
release with respect to the closing of the offering described above. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Inovio Pharmaceuticals, Inc. Press Release dated May 5, 2015</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;5, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d921398dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g921398ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>NEWS RELEASE</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For
Immediate Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals Closes $87.4 Million Underwritten Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; May&nbsp;5, 2015 &#151; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (&#147;Inovio&#148; or the &#147;Company&#148;), today closed
its previously announced underwritten public offering of 10,925,000 shares of the Company&#146;s common stock, including 1,425,000 shares of common stock issued pursuant to the underwriter&#146;s exercise of its option, at the public offering price
of $8.00 per share. The gross proceeds of this offering were $87.4 million. Net proceeds to the Company, after deducting the underwriter&#146;s discounts and commission and other estimated offering expenses payable by the Company, were approximately
$82.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds received from the sale of the common stock for general corporate purposes, including clinical
trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies and technologies that complement its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Jaffray&nbsp;&amp; Co. and Stifel acted as joint bookrunning managers for the offering. H.C. Wainwright&nbsp;&amp; Co., LLC, Brean Capital, LLC and
Maxim Group LLC acted as co-managers of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above were offered by Inovio pursuant to a shelf registration statement
previously filed with and declared effective by the Securities and Exchange Commission (the &#147;SEC&#148;) on August&nbsp;8, 2014. A prospectus supplement and the accompanying prospectus relating to the securities offered has been filed with the
SEC and is available on the SEC&#146;s website at <U>http://www.sec.gov</U>. Copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Piper Jaffray&nbsp;&amp; Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at <U>prospectus@pjc.com</U>; or from Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Attention: Syndicate, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720 or email at <U>syndprospectus@stifel.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This press release does not
constitute an offer to sell or the solicitation of offers to buy any securities of Inovio being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio
Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class
immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product
pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit <U>www.inovio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements under the Private Securities Litigation Reform Act of 1995 relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and
product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials
may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not
necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon&reg; active immune therapy and vaccine products, our ability to
advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope
to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them
will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity
and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other
partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, and other regulatory filings from time to
time. There can be no assurance that any product in Inovio&#146;s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or
that any of the forward-looking information provided herein will be proven accurate. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g921398ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g921398ex99_1logo.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%X`]0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/>Z!$4]U;VJAKB>.$'@%W"Y_.@!Z.DB!T8,A&05.0:`'4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`0->6J7`MVN8EF/2,N`Q
M_"@">@`H`*`"@`H`*`"@`H`*`/*OB"MR/$6Z;=Y!C7R<],8YQ^-5&W41TOP[
M2Z70YC-N$!E_<AO3'./;/]:3W&=A2`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@!K[MC;,!L<9Z9H`\)NDNAJ$J7"R?:]YW`@[BV:O2PCVW2Q<#2;0
M79/VGRE\S/7=CG/O4#+=`!0`4`%`!0`4`%`!0`R2&*9=LL:.OHR@T`.`"@`#
M`'0"@!:`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`(S!"THE,2&
M0=&*C(_&@"2@`H`*`"@`H`*`"@`H`*`..\9>)=0T*]M8K,QA9(RS;TSSFFE<
M#9\,:C<:KH4-Y=%3*Y8':,#@XH:L(T+Z9[?3[F:/&^.)F7/J!FD,X#1?'=]-
MJ2+J4L"6@5F<K'@G`.`.?6JMH!4U/QWJU]<,FG?Z-"#\H5=SD>I/^%"5MQ&?
M#XO\06DN3?.Q'5)5!'\J=D]@/0_#'B:+Q!;.&017<7WT!X(]1[5+5AF_2`*`
M(+N\M["V:XNIEBB7JS?R]S[4XQ<G9";25V<AJ?BK69,C3;&"RA_AGU!B&;W$
M:\C\:Z%"E#XW?T_S,7*I+X5;U_R.8O-2\5N#)_PDVT]ECM=H_E6JJX>+^#\3
M-TZ[7Q_@9A\:>--(8,][%>Q`Y.Z,-^>`"*WA'"5=%HS&4L32U>J.L\-_%?3]
M3E2UU:(6,[<"0',1/UZK^/YUE6P,H*\-472QD9:2T/0P00"#D'H17GG<<1XL
M\1ZUH6J".`PFUE7=&6CR1ZC.?\YJDKB-WPMK9US1UGEVBX1BDH`P,^OY4FK#
M-ND!!>W<5C9374QQ'$A8_A0!YYIOC+7]5U6"RA^S@S/C_5_=7J3U["J:L(]*
MJ1GG&I^-=7M->N;.(P^5'.8US'DXSCUIVTN!Z/2`*`.3\0>.+72I&M;)!=72
M\,<_(A]#ZGZ4TK@<7/XR\07;Y2[9,?PPH!C^M.R0#[7QOKUG(!)<"8#JDR#G
M\1@T[)[".[\/>+[/7"(&7[/>`?ZMCD-_NG^E2U89T5(`H`*`/-OB5_R$K'_K
MDW\ZJ.XCIO`W_(J6W^\__H1HEN"-C5?^01>_]<'_`/034H#Q*PM'O[ZWM(^'
MF<(#Z9[UI>R`]KTS2;/2+1;>TA5`!RV/F8^I-9C*OB+1K?5]*GCDB4S*A,4F
M/F4CD<TT!YKX,NFM/%-H`<"4F-AZY'^.*J6PD>PU`SDO%?Q`T[PK<I:20R75
MTRAC'&0-H[9)_E750PLZRNM$<U;$1I.SW':/JD'C*V34;-6C5#L/F`$PMCD+
MVS@]:BK3E1;@S2G4C5CS(V[?1;&W.[R1))U+OR36!J6_L\!&##'CTVB@#(U3
MPKIVHQG]T(I<<,O%`'B7C'PS-H5Z6*81C@X''UKV<#B'+]W+IL>5BZ"C[\3N
M/A/XIENDDT&\D+M$F^W9CSM'5?PZC\:QQU!1?M(]37!UG)<CZ'8>,M(_M709
M#&N9[?\`>Q^^.H_+^5>:M#T#B?`>K?8-<%J[8AN\)]&_A_P_&JEW$>KU`SAO
MB+JWE6D.EQ-\TQ\R7']T=!^)_E510B+X<Z1M2;595Y/[J+Z?Q'^0_.B3`[ZI
M&>+:[_R-E]_U]'_T*J7P@>TU('->--<?1]($<#;;FY)12.JCN?\`/K32N!Q7
MA'PQ_;MPT]R66RA.&P>7;T_QJF[:(1ZG:65K8Q"*UMXX4'9%Q4#(K_2K'4X3
M%>6R2@]"1R/H>U`'D_B#1)_#.K((I'\L_/!*#@\?U%6M=&(]-\-ZN-:T6&Z;
M'G#Y)0.S#_.?QJ7H,UZ0!0!YM\2O^0E8_P#7)OYU4=Q'3>!O^14MO]Y__0C1
M+<$;&J_\@B]_ZX/_`.@FI0'E'@M0WBNQR,X+'_QTU;V`]BJ!C9/]4_T-`'B_
MAW_D:=._Z^%_G5O81[54#/F7Q/?R:GXGU*[D))>=@,]E!P!^0%?2X>*C2BEV
M/`KRYJDF>T_#/3S8>$8<KCSSYOU)'_ZJ\/%3YZK9[&'AR4TCL:YC<*`"@#A?
MBK:Q2>$GN'`#QNH4_4UUX._MXV.;%?P6>7?#Z5X?'6EE"1ND*GZ%2#7K8M)T
M97/,PMU55CZ+QD8-?/'N'C?B?2VT/Q!(D64C9O-A([#/]#5K56$>HZ-JT>IZ
M'#J#,%^3]Y_LD?>J!GE&HW,_B/Q&[Q`E[B0)$I[+T'Z5>R$>PZ?91:=I\%G"
M,1PH%'O[U`RS0!XMKO\`R-E]_P!?1_\`0JI?"![34@>8?$:5FUVWC)^5(!@?
M4FKB(['P;`D'A2RV@`NI=CZDDU&XS>H`*`.0^(D"2>'XYCC?%,-I^H(/^?:F
MM&!0^&<K>7J,/\(*,/KR#_(4Y;B.^J1A0!YM\2O^0E8_]<F_G51W$=-X&_Y%
M2V_WG_\`0C1+<$;&J_\`((O?^N#_`/H)J4!Y;X$_Y&NU_P!Q_P#T$U;V`]=J
M!C9/]4_T-`'B_AW_`)&C3O\`KX7^=6]A'M#C,;`>AJ!GS#KENUKKE[$P(_>L
M1GT)KZ3#S4Z46CP:\'"HT>^^!+Z*_P#!FFO$1F.,1.!_"R\$?U_&O"Q$'"K)
M,]BA)2IIHZ.L#8*`"@#R_P",EY<K8:?9(I^SNYDD(]1P!^IKTLO4>=M[G#C>
M;D21S'PNTN2Y\4Q790[(`2"1U-;X^JE'V:W,,%2?-SL]WKQCU3E/'ND_;M$^
MUQKF:T.[CNA^]_C^%-.P'`6.NW%CH=]IB9V71!#9^Y_>_,8%6XW8CHOAWI/G
M7<VJ2K\D/R19[L>I_`?SJ9,#TBI&%`'BVN_\C9??]?1_]"JE\('M-2!YW\2;
M%EN+._4?(RF)O8CD?S/Y541&OX`U1+O0_L18>=:DC;ZJ3D'^8I-68SK:0!0!
MP7Q'U1/)M]+1@7+>;(/0=!_6JBA%GX<6+0:3<7C#'VB0!?HO_P!<G\J);@=I
M4C"@#S;XE?\`(2L?^N3?SJH[B.F\#?\`(J6W^\__`*$:);@C8U7_`)!%[_UP
M?_T$U*`\M\"?\C7:_P"X_P#Z":M[`>NU`QLG^J?Z&@#Q?P[_`,C1IW_7PO\`
M.K>PCVJH&>1_$;PDQNS?6Z8#<@]OH:[,+B?8NSV.7$4/:K3<Y;PCXNO?!E^Z
M2PM)9RD>;`>#G^\OO_.O3K488J*<6>?2JSP\K26A[9H_BK1==A5[&_B9CUB<
M[7'L5->-4HSI.TD>K"K":]UFP2%&20`.YK$U,B\\3Z7:SBV2X%U=G[MO;?O'
M/UQT^IQ6L:,Y:VLO,S=2*TZF;?:*WB90]TRPRKP%0[E3V)_B/Z5+LM$4K]31
MT+P[;Z'&WEL7D;@L14E&S2`1T5T9&`*L,$'N*`/%-:T>33=?FTY%+9<>5_M*
M?N_X5HGH(]<T33$TC1[>R7&47+D=V/4_G68S0H`*`/%M=_Y&R^_Z^C_Z%5+X
M0/::D"EJNF0:OITME<`[''##JI[$4`>2W-IJOA'5U;)BD0_)*O*2#^OTK2Z>
M@MCJ;/XE)Y0%[8-Y@ZM"PP?P/2IY6!%J'Q(=XBFG67EN?^6DISC\!1RL#`T7
M0[_Q/J332L_E%LS7#?R'J:INP6/7;:VBL[6*V@0)%$H50.P%9C):`"@#/U'0
M]-U61'OK59F084DD8'X&@"Q96-MIUJMM:1"*%22%!)QGZT`2RQ)-$\4B[D=2
MK#U!ZT`9MGX:T?3[I+FUL4CF3.U@Q.,C'<T`:M`!C(P:`,>#PMHEK<I<PV")
M-&VY6#-P?SH`V*`(KBWBNH&AF0/&PY!H`X76OAU'<EVM"K(>D;CI^-:0J2@[
MQ=B90C-6DCE)/AS<1R'.GS\'(,3UU+'5DM;,YG@Z3U1>M/`;;@)-.O91Z37!
M"_D,5+QE1[67R*6%IKN=IH_A864`B*0VD/>*W7&[ZMU-<\ZDIN\G<WC&,%:*
M.EBB2&,1QJ%4=`*S*'T`%`!0!FW>BVUYK%EJ4G^MM00HQP<]/RZT`:5`!0`4
M`8\WA;1;BZ>YEL%:9VWLVYN3Z]:`-B@`H`AN;6WO(&AN84FB/577(H`YRX^'
M^AS.619X,]HY./U!IW`?:^`]"MG#-#).1VE?(_(8HN!T<44<$2Q11K'&HPJJ
M,`?04@'T`%`!0!RNJ6?AFPO"MZMR)71IVV2SL%7."QVG"C)K55II?\`S]E%O
M8O+X5T5T5TBF96&01=RD$?\`?5/VT^_X(7LH=B"/0O#TK72HLQ-HVR;_`$F;
MY3M#?WO0@T>VGW_!![*'8DMO#>A7EK#<P1S/#,@D1OM4W*D9!^]Z4>VGW_!!
M[*'8BO=#\-Z;%')>%X$DD6)"]W*`78X4?>[FCVT_Z2#V4.Q9_P"$3T?_`)X3
M_P#@5+_\51[:??\`!![*'8SM0T_POI4Z17:W*,T;2_+-.P5!@%B03@<CDT>V
MGW_!![*'8T%\*Z*Z*Z13,K#((NY2"/\`OJCVT^_X(/90[$/_``C_`(>^W_8<
M2?:O+\WROM<N=F<9^]TSQ1[:??\`!![*'8+?P_X>NWG2W\R1K>0Q2A;N4['`
M!P?FZX(H]M/O^"#V4.Q/_P`(GH__`#PG_P#`J7_XJCVT^_X(/90[%:PT/PWJ
MEFMW8F2>W8D!TNY<$@D'^+U!H]M/O^"#V4.Q--X9T*V@>:9)(XHU+.[7DH"@
M=23NH]M/O^"#V4.Q1L].\-7TR1PP7P\P$QL[W**X'HQ.#1[:?])![*'8O3>&
M-#MX))I8IECC4LS?:IN`!DG[U'MI]_P0>RAV*NG:/X?U2/S+>UOA&5#*TLEQ
M&&!Z$%B,T>VGW_!![*'8GN_#V@6-L;BY29(E*J6^U3'!)`'\7J11[:??\$'L
MH=@/A[0%O4LS'-Y[QM*$^U3<J"`3][U84>VG_20>RAV'7'AG1;:!I6MKIPO:
M.XF=C]`&R:/;3[_@@]E#L5M+TGP[K%K]ILX+PPG[K/+.@;Z9(S1[:??\$'LH
M=B:?P_X?MIK:&5)EDN',<0^U3?,P4MC[WHIH]M/O^"#V4.Q/_P`(GH__`#PG
M_P#`J7_XJCVT^_X(/90[&6MIX6DF"11WDJ%_+\Z.2X:+=G&-X..O'7%'MI]_
MP0>RAV-3_A$]'_YX3_\`@5+_`/%4>VGW_!![*'8K-H?AM-1CTYBXO)(S*D1N
MY=Q0$`G[WJ11[:??\$'LH=BS_P`(GH__`#PG_P#`J7_XJCVT^_X(/90[$%OX
M?\/W;W"0),S6\GE2#[5,-K8!Q][T84>VGW_!![*'8==>'-`LK66YN5EB@B4L
M[M=RX`'_``*CVT^_X(/90[!I.EZ+)-]ILX+N.6!ONSO,I4X_NN>>#2=6;5F-
M4XQ=T=!61H%`'.ZIH#ZKXDCGF>9+'[$T+^5-LWDN#M..<8S0!T$<:0Q)%&H2
M-`%51T`'04`<U_PC3SWFNSSO<Q_:IMT(ANWC5E\I%Y"D#.0>M`&QHEM+9:#I
MUK.H6:"VCC<`YPP4`\_A0!CZYH-]X@U-EEFCM[""$QQAHQ)YCN,,^,C:5'`/
MN:`-G1Q?)I4$6I8-W$#&[@Y$F#@/[;@`<=LT`87B?0-0U75(KBT=EBBM'1XQ
M+L6XRZDQ,1R`P!Y'2@#I[<!;:)1%Y("`>7Q\G'3CCB@#E=4T35I=:OM<L5B&
MHV_EQV/FM\KQA3O5L=`2Y_%%H`N>'-!ET"^O8E^>VN(XI6E)Y>?YA(Q'J?E-
M`%_7[>^O-*>RT]O*EN2(GFR/W*'[S`=SC@#U(H`H:%H]]H>J7,6Z*73KA!(/
M*C$0AD4!<!<GAE`.?53ZT`:.NZ=)JNCRVD3HLI9'3?\`=)5@P#>QVX/L:`"S
MO[^XG2.?2);9<'S)'E1E!]%P23^(%`$^IPR7.E7D$0!DDA=%![DJ0*`,GPK9
MSV-A'!<6=[;R)#&C?:+H3*2!@[1O;'Y"@"[X@L9]0T2>WMMIGRCH&.`Q5PV,
M]L[<?C0!7M([Z\\0IJ,]BUG##:M`%E=6=V9E)(VD@`;/7G/2@#;H`R_#MG/I
M_A^SM+E0DT288`YP<GO0`FJ64]UJ>C31*#':W+22DG&%,3J/KRPH`T;B+S[:
M6'>R>8A7<O49&,B@#$TAM4TVPL]+DTDN;=4A^T12H(B@P-V"=P..<8_'O0!O
MT`<7/X>URXN)M;%Q#'J*SB:"W*`D(F56+S,\!E+9XZN?2@#LU)*@E2I(Y![4
M`8ND17EIJVK1S63K!<71GCG#H5(\M%QC.X'*GM0!?U6)I]*N85M([LNA4P2-
MM60=QGMQ0!G^'K>_@DO//2XAL24^S0W,PED0X.[Y@3\O3`))X/K0!N4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%
)`!0`4`%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
